PURPOSE: High-dose interleukin-2 (IL-2) induces responses in 15% to 20% of patients with advanced melanoma; 5% to 8% are durable complete responses (CRs). The HLA-A2-restricted, modified gp100 peptide (210M) induces T-cell immunity in vivo and has little antitumor activity but, combined with high-dose IL-2, reportedly has a 42% (13 of 31 patients) response rate (RR). We evaluated 210M with one of three different IL-2 schedules to determine whether a basis exists for a phase III trial. PATIENTS AND METHODS: In three separate phase II trials, patients with melanoma received 210M subcutaneously during weeks 1, 4, 7, and 10 and standard high-dose IL-2 during weeks 1 and 3 (trial 1), weeks 7 and 9 (trial 2), or weeks 1, 4, 7, and 10 (trial 3). Immune assays were performed on peripheral-blood mononuclear cells collected before and after treatment. RESULTS: From 1998 to 2003, 131 patients with HLA-A2-positive were enrolled. With 60-month median follow-up time, the overall RR for 121 assessable patients was 16.5% (95% CI, 10% to 26%); the RRs were 23.8% in trial 1 (42 patients), 12.5% in trial 2 (40 patients), and 12.8% in trial 3 (39 patients). There were 11 CRs (9%) and nine partial responses (7%), with 11 patients (9%) progression free at >or= 30 months. Immune studies including assays of CD3-zeta expression and numbers of CD4(+)/CD25(+)/FoxP3(+) regulatory T cells, CD15(+)/CD11b(+)/CD14(-) immature myeloid-derived cells, and CD8(+)gp100 tetramer-positive cells in the blood did not correlate with clinical benefit. CONCLUSION: The results again demonstrate efficacy of high-dose IL-2 in advanced melanoma but did not demonstrate the promising clinical activity reported with vaccine and high-dose IL-2 in any of three phase II trials.
PURPOSE: High-dose interleukin-2 (IL-2) induces responses in 15% to 20% of patients with advanced melanoma; 5% to 8% are durable complete responses (CRs). The HLA-A2-restricted, modified gp100 peptide (210M) induces T-cell immunity in vivo and has little antitumor activity but, combined with high-dose IL-2, reportedly has a 42% (13 of 31 patients) response rate (RR). We evaluated 210M with one of three different IL-2 schedules to determine whether a basis exists for a phase III trial. PATIENTS AND METHODS: In three separate phase II trials, patients with melanoma received 210M subcutaneously during weeks 1, 4, 7, and 10 and standard high-dose IL-2 during weeks 1 and 3 (trial 1), weeks 7 and 9 (trial 2), or weeks 1, 4, 7, and 10 (trial 3). Immune assays were performed on peripheral-blood mononuclear cells collected before and after treatment. RESULTS: From 1998 to 2003, 131 patients with HLA-A2-positive were enrolled. With 60-month median follow-up time, the overall RR for 121 assessable patients was 16.5% (95% CI, 10% to 26%); the RRs were 23.8% in trial 1 (42 patients), 12.5% in trial 2 (40 patients), and 12.8% in trial 3 (39 patients). There were 11 CRs (9%) and nine partial responses (7%), with 11 patients (9%) progression free at >or= 30 months. Immune studies including assays of CD3-zeta expression and numbers of CD4(+)/CD25(+)/FoxP3(+) regulatory T cells, CD15(+)/CD11b(+)/CD14(-) immature myeloid-derived cells, and CD8(+)gp100 tetramer-positive cells in the blood did not correlate with clinical benefit. CONCLUSION: The results again demonstrate efficacy of high-dose IL-2 in advanced melanoma but did not demonstrate the promising clinical activity reported with vaccine and high-dose IL-2 in any of three phase II trials.
Authors: John D Roberts; Donna Niedzwiecki; William E Carson; Paul B Chapman; Thomas F Gajewski; Marc S Ernstoff; F Stephen Hodi; Christopher Shea; Stanley P Leong; Jeffrey Johnson; Dongsheng Zhang; Alan Houghton; Frank G Haluska Journal: J Immunother Date: 2006 Jan-Feb Impact factor: 4.456
Authors: Jens Dannull; Zhen Su; David Rizzieri; Benjamin K Yang; Doris Coleman; Donna Yancey; Aijing Zhang; Philipp Dahm; Nelson Chao; Eli Gilboa; Johannes Vieweg Journal: J Clin Invest Date: 2005-11-23 Impact factor: 14.808
Authors: M B Atkins; M T Lotze; J P Dutcher; R I Fisher; G Weiss; K Margolin; J Abrams; M Sznol; D Parkinson; M Hawkins; C Paradise; L Kunkel; S A Rosenberg Journal: J Clin Oncol Date: 1999-07 Impact factor: 44.544
Authors: K A Margolin; A A Rayner; M J Hawkins; M B Atkins; J P Dutcher; R I Fisher; G R Weiss; J H Doroshow; H S Jaffe; M Roper Journal: J Clin Oncol Date: 1989-04 Impact factor: 44.544
Authors: Douglas J Schwartzentruber; David H Lawson; Jon M Richards; Robert M Conry; Donald M Miller; Jonathan Treisman; Fawaz Gailani; Lee Riley; Kevin Conlon; Barbara Pockaj; Kari L Kendra; Richard L White; Rene Gonzalez; Timothy M Kuzel; Brendan Curti; Phillip D Leming; Eric D Whitman; Jai Balkissoon; Douglas S Reintgen; Howard Kaufman; Francesco M Marincola; Maria J Merino; Steven A Rosenberg; Peter Choyke; Don Vena; Patrick Hwu Journal: N Engl J Med Date: 2011-06-02 Impact factor: 91.245
Authors: Sarah E Church; Shawn M Jensen; Christopher G Twitty; Keith Bahjat; Hong-Ming Hu; Walter J Urba; Bernard A Fox Journal: Cancer J Date: 2011 Sep-Oct Impact factor: 3.360
Authors: Fan Zhou; Juan Hu; Jiang-Hua Shao; Shu-Bing Zou; Shun-Li Shen; Zhi-Qiang Luo Journal: J Cancer Res Clin Oncol Date: 2012-06-27 Impact factor: 4.553
Authors: Antoni Ribas; Begoña Comin-Anduix; Bartosz Chmielowski; Jason Jalil; Pilar de la Rocha; Tara A McCannel; Maria Teresa Ochoa; Elizabeth Seja; Arturo Villanueva; Denise K Oseguera; Bradley R Straatsma; Alistair J Cochran; John A Glaspy; Liu Hui; Francesco M Marincola; Ena Wang; James S Economou; Jesus Gomez-Navarro Journal: Clin Cancer Res Date: 2009-09-29 Impact factor: 12.531
Authors: Marta Batus; Salman Waheed; Carl Ruby; Lindsay Petersen; Steven D Bines; Howard L Kaufman Journal: Am J Clin Dermatol Date: 2013-06 Impact factor: 7.403